Acquisitions - Kinnate Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | ||
|---|---|---|---|
Apr. 30, 2024 |
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Asset Acquisition | |||
| Exarafenib milestone contingent consideration | $ 3,704 | $ 3,600 | |
| CVR Agreement | Kinnate CVR holders | |||
| Asset Acquisition | |||
| Exarafenib milestone contingent consideration | $ 3,700 | $ 3,600 | |
| Kinnate | |||
| Asset Acquisition | |||
| Asset acquisition, share price (in dollars per share) | $ 2.5879 | ||
| Total purchase consideration | $ 126,400 | ||
| Net proceeds from specified assets (as a percent) | 85.00% | ||
| Kinnate | CVR Agreement | Kinnate CVR holders | |||
| Asset Acquisition | |||
| Percentage share from potential milestone | 100.00% | ||
| Cash received from milestone payments | $ 30,500 |
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid in asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Represents the percentage share from potential milestone proceeds. No definition available.
|
| X | ||||||||||
- Definition Percentage Share of Proceeds from Specified Assets No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow from milestone payments received net. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|